GlassScriptPhysician profile
John A Adiet
NPI 1245429158
$3,803.91
in general payments reported to CMS, 2019-2025
31 companies · $645 in 2025
The $645 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $781 · 2020: $348 · 2021: $347 · 2022: $273 · 2023: $626 · 2024: $783 · 2025: $645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,045 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,045.13 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,062.01 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $537.82 | 2020-2024 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $292.45 | 2020-2025 | |
| Lilly USA, LLC | $274.02 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Smith+Nephew, INC. | $213.86 | 2019-2025 | Renasys Touch |
| Abbott Laboratories | $153.73 | 2021-2025 | Freestyle Libre 3 |
| Amgen INC. | $140.04 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $134.90 | 2019 | |
| Boston Scientific Corporation | $123.41 | 2019 | |
| Abbvie INC. | $112.76 | 2022 | |
| Amarin Pharma, INC. | $102.60 | 2019 | |
| Vivus LLC | $97.14 | 2023 | Qsymia |
| Janssen Pharmaceuticals, INC | $91.36 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $53.04 | 2023-2024 | Contrave, Onzetra Xsail |
| Glaxosmithkline, LLC. | $44.76 | 2022-2023 | Arexvy, Shingrix |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $40.04 | 2021-2024 | Dexcom G6 Transmitter |
| Kci USA, INC. | $33.80 | 2019-2020 | |
| Tactile Systems Technology INC | $27.26 | 2019 | |
| Azurity Pharmaceuticals, INC. | $26.82 | 2025 | Alvesco |
| Allergan, INC. | $26.22 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $24.83 | 2025 | Zoryve |
| Idorsia Pharmaceuticals US INC | $24.68 | 2022 | |
| Exact Sciences Corporation | $23.40 | 2023 | Cologuard Collection Kit |
| Organogenesis INC. | $23.33 | 2020 | |
| Paratek Pharmaceuticals, INC. | $22.86 | 2025 | Nuzyra |
| Xeris Pharmaceuticals, INC. | $22.11 | 2022 | |
| Insulet Corporation | $17.76 | 2020 | |
| Strongbridge US INC. | $17.43 | 2020 | |
| Cashflow Solutions, LLC | $14.45 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.75 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Adiet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.